Cortistatin (CST-14 / CST-17)

Cortistatin is a somatostatin-related neuropeptide existing as 14- or 17-amino acid isoforms (CST-14, CST-17). Despite sharing 11 of 14 residues with somatostatin, cortistatin is encoded by a distinct gene and exhibits unique anti-inflammatory, neuromodulatory, and sleep-promoting properties, including binding to the ghrelin receptor (GHSR-1a).

Overview

Cortistatin was named for its predominant expression in the cerebral cortex ("cortex" + "statin" for its inhibitory activity). Although structurally similar to somatostatin, cortistatin has a distinct expression pattern — it is found primarily in cortical and hippocampal GABAergic interneurons, whereas somatostatin has broader CNS and peripheral distribution. The two peptides arise from separate genes through independent evolutionary duplication, and cortistatin knockout mice exhibit phenotypes distinct from somatostatin knockouts, confirming non-redundant biological roles.

A key distinguishing feature of cortistatin is its ability to bind the growth hormone secretagogue receptor (GHSR-1a), the ghrelin receptor. This interaction is not shared by somatostatin and provides cortistatin with unique neuroendocrine and metabolic signaling properties. Cortistatin has also emerged as a potent endogenous anti-inflammatory mediator, with therapeutic relevance in autoimmune and neurodegenerative disease models.

Mechanism of Action

Cortistatin exerts its effects through multiple receptor systems:

  • Somatostatin receptors (SSTR1–5): Cortistatin binds all five SSTRs with affinity comparable to somatostatin, inhibiting adenylate cyclase via Gi/Go-coupled signaling. This mediates growth hormone suppression, anti-proliferative effects, and modulation of neurotransmitter release de Lecea et al. (1996).
  • Ghrelin receptor (GHSR-1a): Unlike somatostatin, cortistatin binds GHSR-1a, functioning as a partial agonist. This interaction influences appetite, reward signaling, and neuroendocrine regulation, positioning cortistatin at the intersection of somatostatin and ghrelin signaling Deghenghi et al. (2001).
  • MrgX2 receptor: Cortistatin activates Mas-related gene X2, a receptor not shared with somatostatin. This may mediate some of cortistatin's unique pain-modulating and immune effects Robas et al. (2003).
  • Anti-inflammatory signaling: Cortistatin suppresses NF-κB-driven pro-inflammatory cytokine production (TNF-α, IL-6, IL-12) in macrophages and dendritic cells, promotes Treg generation, and inhibits Th1/Th17 differentiation through cAMP-dependent and independent pathways Gonzalez-Rey et al. (2006).
  • Cortical inhibition: Cortistatin depresses cortical activity and enhances slow-wave sleep through mechanisms distinct from somatostatin, potentially involving adenosine receptor signaling and modulation of acetylcholine release.

Reconstitution Calculator

Research

Anti-inflammatory and Autoimmune Effects

Cortistatin has demonstrated potent anti-inflammatory activity in multiple autoimmune models. In experimental autoimmune encephalomyelitis (EAE), cortistatin treatment reduced clinical severity, demyelination, and CNS inflammatory infiltrates by suppressing encephalitogenic Th1/Th17 responses and promoting regulatory T cell generation Gonzalez-Rey et al. (2006). In collagen-induced arthritis, cortistatin reduced joint inflammation, synovial hyperplasia, and cartilage destruction with efficacy comparable to or exceeding somatostatin Gonzalez-Rey et al. (2007). In sepsis models, cortistatin improved survival and reduced multi-organ damage by suppressing inflammatory cytokine cascades Gonzalez-Rey et al. (2006).

Cortical Activity and Cognition

Cortistatin selectively depresses cortical neuronal firing rates when applied locally to cortical neurons. In hippocampal studies, cortistatin modulates long-term potentiation (LTP) and synaptic plasticity de Lecea et al. (1996). Cortistatin-deficient mice show enhanced hippocampal-dependent learning in some paradigms but also exhibit increased susceptibility to seizures, suggesting cortistatin normally balances excitatory/inhibitory tone in cortical circuits. These cognitive effects distinguish cortistatin from somatostatin, which has different effects on memory consolidation.

Ghrelin Receptor Interaction

Cortistatin's ability to bind GHSR-1a distinguishes it fundamentally from somatostatin. Through this receptor, cortistatin can modulate growth hormone secretion, appetite signaling, and reward circuits. However, cortistatin acts as a partial agonist or functional antagonist at GHSR-1a rather than a full agonist like ghrelin, potentially serving as an endogenous brake on ghrelin-driven feeding behavior and GH pulsatility Deghenghi et al. (2001). This dual receptor profile — activating both somatostatin and ghrelin receptors — makes cortistatin a unique integrator of growth, metabolic, and immune signaling.

Neurodegeneration and Alzheimer's Disease

Cortistatin levels are altered in Alzheimer's disease brain tissue, with reductions in cortistatin-expressing interneurons in the cortex and hippocampus. Given cortistatin's role in modulating cortical excitability, sleep architecture, and neuroinflammation — all disrupted in Alzheimer's — cortistatin deficiency may contribute to disease pathology. Research has shown that cortistatin administration reduces neuroinflammation and amyloid-associated pathology in preclinical models, with effects mediated through both anti-inflammatory activity and modulation of neuronal network dynamics Burgos-Ramos et al. (2008).

Sleep and EEG Effects

Cortistatin was originally characterized for its ability to induce slow-wave sleep. Intracerebroventricular administration of cortistatin in rats enhances slow-wave activity in EEG recordings and promotes non-REM sleep without affecting REM sleep architecture de Lecea et al. (1996). This effect is distinct from somatostatin, which does not promote sleep at comparable doses. The sleep-promoting mechanism may involve antagonism of cholinergic wake-promoting circuits and enhancement of adenosinergic signaling in the basal forebrain.

Immunoregulation and inflammation

Cortistatin is produced by and binds to immune cells and acts as an endogenous anti-inflammatory factor. It downregulates Th1 and inflammatory mediators and is protective across multiple experimental inflammatory and autoimmune disorders, making it a candidate template for immunomodulatory therapeutics.

  • Detected in lymphocytes, monocytes, macrophages and dendritic cells (unlike somatostatin)
  • Ameliorates experimental colitis more effectively than somatostatin or octreotide (PMID 16537513)
  • Analog engineering is being pursued to improve stability and immunoregulatory potency

Somatostatin-family pharmacology and CNS function

Cortistatin is a cyclic neuropeptide encoded by a distinct gene from somatostatin, sharing structural homology and binding all five somatostatin receptors (plus additional targets such as the ghrelin receptor and MrgX2), yet exerting unique CNS effects including slow-wave sleep induction and cortical depression.

  • Binds all five somatostatin receptor subtypes but shows distinct functional actions
  • Induces non-REM slow-wave sleep, opposite to somatostatin's sleep EEG effects
  • Expressed predominantly in cortical and hippocampal inhibitory interneurons

Pain modulation

Beyond sleep and immunity, cortistatin modulates nociception, raising pain thresholds centrally and alleviating neuropathic pain peripherally, in part via its combined analgesic and anti-inflammatory actions.

  • ICV cortistatin raises pain thresholds in rats (PMID 14700741)
  • Reduces mechanical/thermal hypersensitivity and neuroinflammation after nerve injury (PMID 34202793)

Safety Profile

Cortistatin has shown a favorable safety profile in preclinical studies. As a naturally occurring neuropeptide with rapid plasma degradation, toxicity at research doses has not been reported. Key considerations include:

  • GH suppression: As an SSTR agonist, cortistatin can suppress growth hormone release, though this effect is transient at typical research doses.
  • Sedation: Sleep-promoting effects may cause sedation, consistent with its physiological role.
  • Cardiovascular: Mild hypotension has been observed in some preclinical models, consistent with vasodilatory properties.
  • No clinical trial data: Cortistatin has not advanced to human clinical trials. All safety data derive from preclinical models.
  • Immunosuppression: Potent anti-inflammatory effects could theoretically impair host defense in immunocompromised settings, though this has not been observed in preclinical infection models.

Pharmacokinetic Profile

Cortistatin (CST-14 / CST-17) — Pharmacokinetic Curve

Intraperitoneal, Intracerebroventricular (research)
0%25%50%75%100%0m4m7m11m14m18mTimeConcentration (% peak)T_max 2mT_1/2 4m
Half-life: 4mT_max: 2mDuration shown: 18m

Quick Start

Route
Intraperitoneal, Intracerebroventricular (research)

Research Indications

Primary Research Areas

Emerging
Inflammatory and autoimmune disease

Endogenous anti-inflammatory neuropeptide protective in preclinical colitis, sepsis, arthritis and other immune-mediated models.

Emerging
Sleep and neurophysiology

Induces slow-wave (non-REM) sleep and depresses cortical activity, with effects on sleep EEG opposite to somatostatin.

Emerging
Analgesia / neuropathic pain

Raises pain threshold and alleviates neuropathic pain and associated neuroinflammation in rodent models.

Research Protocols

intracerebroventricular Injection

Intracerebroventricular administration of cortistatin in rats enhances slow-wave activity in EEG recordings and promotes non-REM sleep without affecting REM sleep architecture [de Lecea et al.

intraperitoneal Injection

Administered via intraperitoneal.

What to Expect

What to Expect

Onset

Rapid onset expected; half-life of ~2–5 minutes (plasma, estimated) indicates fast-acting pharmacokinetics

Daily Use

Due to short half-life (~2–5 minutes (plasma, estimated)), effects are expected per-dose; consistent daily administration maintains therapeutic levels

Ongoing

Regular administration schedule required; effects are dose-dependent and do not persist between doses

Quality Indicators

What to look for

  • Human clinical trials conducted
  • Well-established safety profile
  • Naturally occurring compound
  • Extensive peer-reviewed research base

Frequently Asked Questions

References (15)

  1. [10]
  2. [1]
    de Lecea L, Criado JR, Prospero-Garcia O, et al A cortical neuropeptide with neuronal depressant and sleep-modulating properties Nature (1996)
  3. [3]
  4. [4]
    Gonzalez-Rey E, Chorny A, Robledo G, Delgado M Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia J Exp Med (2006)
  5. [5]
  6. [6]
    Burgos-Ramos E, Hervás-Aguilar A, Aguado-Llera D, et al Somatostatin and Alzheimer's disease Mol Cell Endocrinol (2008)
  7. [7]
    Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M Therapeutic effect of cortistatin in experimental autoimmune encephalomyelitis Brain Behav Immun (2006)
  8. [2]
  9. [9]
  10. [8]
    Morell M et al — Cortistatin as a novel multimodal therapy for inflammatory and neurodegenerative diseases Mol Cell Endocrinol (2022)
  11. [11]
    Souza-Moreira L et al — Cortistatin in metabolic inflammation: protective role in obesity-associated adipose tissue dysfunction Front Immunol (2022)
  12. [12]
    Méndez-Díaz M, Guevara-Martínez M, Alquicira CR, Guzmán Vásquez K, Prospéro-García O Cortistatin, a modulatory peptide of sleep and memory, induces analgesia in rats Neuroscience Letters (2004)

    Intracerebroventricular cortistatin raised the pain threshold in rats, indicating the peptide participates in pain-perception regulation in addition to its established roles in sleep and memory.

  13. [13]
    Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease Proceedings of the National Academy of Sciences USA (2006)

    Cortistatin ameliorated clinical and histologic severity of murine colitis and improved survival, outperforming somatostatin and octreotide, establishing it as an endogenous anti-inflammatory neuropeptide with therapeutic potential in IBD.

  14. [14]
    de Lecea L Cortistatin--functions in the central nervous system Molecular and Cellular Endocrinology (2008)

    Review of cortistatin's cortex- and hippocampus-restricted expression and its distinct CNS actions—slow-wave sleep induction, reduced locomotion and cortical depression—that oppose or diverge from somatostatin despite binding the same receptors.

  15. [15]
    Falo CP, Benitez R, Caro M, Morell M, Forte-Lago I, Hernandez-Cortes P, et al. The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury Pharmaceutics (2021)

    Cortistatin reduced mechanical and thermal hypersensitivity and neuroinflammation in rodent peripheral nerve injury models, supporting it as an endogenous analgesic and anti-inflammatory mediator in neuropathic pain.

Updated 2026-07-07Reviewed by ai-refresh-2026-077 citationsSources: https://pubmed.ncbi.nlm.nih.gov/16537513/, https://pubmed.ncbi.nlm.nih.gov/18374474/

On this page